Inhibition of PLK1 Destabilizes EGFR and Sensitizes EGFR-Mutated Lung Cancer Cells to Small Molecule Inhibitor Osimertinib

SIMPLE SUMMARY: Despite the clinical use of epidermal growth factor receptor (EGFR) inhibitors for non-small cell lung cancer (NSCLC) patients, this disease remains incurable due to the development of resistance mechanisms to treatment. We demonstrate that the inhibition of polo-like kinase 1 (PLK1)...

Descripción completa

Detalles Bibliográficos
Autores principales: Eggermont, Carolien, Gutierrez, Gustavo J., De Grève, Jacques, Giron, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177332/
https://www.ncbi.nlm.nih.gov/pubmed/37174055
http://dx.doi.org/10.3390/cancers15092589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177332/
https://www.ncbi.nlm.nih.gov/pubmed/37174055
http://dx.doi.org/10.3390/cancers15092589

Ejemplares similares